---
title: >-
  ceo of global pharmaceutical giant merck, ken frazier, speaking about a
  potential covid-19 treatment.
description: >-
  We understand the urgency, but our goal isn’t to be the frontrunner in the
  early stages — it’s to develop a vaccine that is safe and effective.
aliases:
  - >-
    article/ceo-of-global-pharmaceutical-giant-merck-ken-frazier-speaking-about-a-potential-covid-19-treatment/
published: true
date: '2020-05-28T01:58:20+00:00'
publishDate: '2020-05-28T01:58:20+00:00'
lastmod: '2020-05-28T02:24:51+00:00'
tags: []
post_author: []
section: quickquotes
is_breaking: false
featured_image:
  image: >-
    https://smarthernews.com/wp-content/uploads/2018/08/pexels-photo-415816-e1586034030296.jpeg
  alt: ''
featured_quote:
  quote: >-
    We understand the urgency, but our goal isn’t to be the frontrunner in the
    early stages — it’s to develop a vaccine that is safe and effective.
  summary: >-
    CEO of global pharmaceutical giant Merck, Ken Frazier, speaking about a
    potential COVID-19 treatment.
  citation: ''
---
*   [Frazier](\"https://www.merck.com/about/leadership/board-of-directors/home.html\") recently did a series of interviews as the company continues to push into the competitive space for a COVID-19 treatment.
*   Merck recently bought a European company working on a COVID-19 vaccine.
*   Merck also partnered with a smaller U.S. company working on an antiviral treatment for COVID-19; unlike remdesevir, this treatment does not have to be administered through an IV.
*   **Why It Matters:** Frazier, although optimistic about COVID-19 pharmaceuticals, underscored the need for safety and efficiency when millions – and potentially billions – of people may eventually need the treatments developed. He said in an interview with _The Financial Times_ that 12-18 months to develop a safe and effective vaccine was “very aggressive” and a timeline he did not want to commit his company too.

Read more of his _Financial Times_ interview [HERE](\"https://www.ft.com/content/7b72a568-9eed-460f-b100-7bf74e3f4cbf\")